• Standard BioTools agreed to sell its Mass Cytometry business to Multiplex Bio as it advances a planned merger with Treeline.
• Deal valued at up to USD 10 million, including a seller's note from Multiplex Bio and a potential milestone payment.
• Standard BioTools to provide a working capital loan of up to USD 10 million at closing.
• CyTOF and Hyperion product lines to continue under the Standard BioTools brand, with most of the Mass Cytometry team transferring.
• Closing targeted by end-2026, substantially concurrent with the Treeline transaction, subject to stockholder approval and customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.